Dr. Toni Choueiri on Cabozantinib Versus Everolimus in Renal Cell Carcinoma
Toni Choueiri, MD, Clinical Director, Lank Center for Genitourinary Oncology Director, Kidney Cancer Center, Senior Physician at Dana-Farber Cancer Institute, discusses the results of the METEOR trial in advanced renal cell carcinoma (RCC).
Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Senior Physician at Dana-Farber Cancer Institute, discusses the results of the phase III METEOR trial that assessed cabozantinib for patients with advanced renal cell carcinoma (RCC).
The open-label phase III trial looked at cabozantinib, which inhibits multiple tyrosine kinases, including MET, VEGFRs, and AXL, compared with everolimus, a current standard of care, in 658 pretreated patients with RCC. Cabozantinib was investigated because VEGFR-resistance is common in RCC, making a novel VEGFR-inhibitor an unmet need, says Choueiri.
The primary endpoint of the trial was progression-free survival (PFS). The study found a 42% reduction in the risk of death or progression with cabozantinib compared to everolimus. The estimated median PFS among the first 375 randomized patients was 7.4 months with cabozantinib compared with 3.8 months for patients receiving everolimus (HR, 0.58; 95% CI, 0.45-0.75; P <.001).
<<<
